Potential of endogenous regenerative technology for in situ regenerative medicine
Endogenous regenerative technology involves the use of a patient's biologically active proteins, growth factors and biomaterial scaffolds.
Search
- Mar 18
Antabuse may help revive vision in people with progressive blinding disorders
UC Berkeley researchers have found that a drug once widely used to wean alcoholics off drinking may help improve sight in mice with RD.
- Aug 16, 2021
New Treatments for Retinitis Pigmentosa
Existing treatments only help a fraction of the estimated 100,000 Americans with this condition. But advances in gene therapy may soon help.
- Mar 15, 2021
FDA grants orphan drug designation for RP treatment
The FDA has granted orphan drug designation for chemically induced photoreceptor-like cells to treat retinitis pigmentosa.
- Jul 15, 2018
Understanding the molecular mechanisms underlying retina degeneration in INPP5E-Joubert Syndrome
Our goal is to identify the onset of degeneration and devise gene-based therapies to ameliorate or cure the retina disease.
- Apr 1, 2018
First Gene Therapy FDA-Approved for an Inherited Retinal Disease
In 1972, Friedman and Roblin proposed that it was theoretically possible to introduce “good” DNA to replace defective DNA.
- Dec 19, 2017
FDA Approves Gene Therapy for Inherited Blindness Developed by the UPenn and CHOP
In 2017, the FDA approved a gene therapy for RP caused by RPE65. The decision marked the first approved treatment for any form RP.
- Jun 30, 2013
Stem Cell Therapy: Novel Approach, RP Vision Restoration
Medical Hypothesis, Discovery Innovation Ophthalmology Journal | Harvey Siy Uy, MD, Pik Sha Chan, MD, and Franz Marie Cruz, MD | 2013...
- May 16, 2011
Scientists for the First Time Regenerate Sections of Retinas and Increase Visual Function With Stem
Fierce Biotech | May 16, 2011, 08:05 am | Boston | PRNewswire-US Newswire Scientists from Schepens Eye Research Institute are the first...
- Oct 1, 2010
Regenerative Therapy for Retinal Disorders
Discusses stem cells, dev stages of the eye field, eye field transcriptional factors, and endogenous and exogenous sources of stem cells.